Results 111 to 120 of about 9,596 (243)

Activation and dysregulation of innate immunity in HIV-1 and HIV-2 infections [PDF]

open access: yes, 2010
Toll-like receptors (TLRs) are pattern recognition receptors, expressed by antigen presenting cells (APCs) that recognize conserved molecular patterns of diverse microorganisms.
Nowroozalizadeh, Salma
core   +1 more source

A Protective Allergy Vaccine Based on CpG- and Protamine-Containing PLGA Microparticles [PDF]

open access: yes, 2018
Purpose: Allergen-specific immunotherapy (SIT) requires dozens of subcutaneous injections over 3 to 5years in order to control IgE-mediated hypersensitivity, which is a T-helper 2 (Th2)-associated pathology.
Csaba, Noèmi   +6 more
core   +1 more source

Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy [PDF]

open access: yes, 2011
Immunostimulatory therapies that activate immune response pathways are of great interest for overcoming the immunosuppression present in advanced tumors.
Irvine, Darrell J   +2 more
core   +1 more source

A toll-like receptor 9 antagonist reduces pain hypersensitivity and the inflammatory response in spinal cord injury

open access: yesNeurobiology of Disease, 2013
Toll-like receptors (TLRs) are mediators of the innate immune response to exogenous pathogens. They have also been implicated in sterile inflammation associated with systemic injury and non-infectious diseases via binding of endogenous ligands, possibly ...
Brian T. David   +7 more
doaj   +1 more source

Pathogen- and Host-Directed Antileishmanial Effects Mediated by Polyhexanide (PHMB) [PDF]

open access: yes, 2015
BACKGROUND:Cutaneous leishmaniasis (CL) is a neglected tropical disease caused by protozoan parasites of the genus Leishmania. CL causes enormous suffering in many countries worldwide. There is no licensed vaccine against CL, and the chemotherapy options
A Ponte-Sucre   +63 more
core   +4 more sources

Sharpening up tumor microenvironment to enhance the efficacy of immune checkpoint blockade on head and neck cancer using a CpG-oligodeoxynucleotide. [PDF]

open access: yesCancer Immunol Immunother, 2022
Tseng JC   +9 more
europepmc   +1 more source

A CpG oligodeoxynucleotide inducing anti-coxsackie B3 virus activity in human peripheral blood mononuclear cells [PDF]

open access: bronze, 2007
Zhongyi Cong   +10 more
openalex   +1 more source

Home - About - Disclaimer - Privacy